Cycurion, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Cycurion announced approximately $800,000 in annual contract spend across three engagements: (1) a pharmaceutical AI Center of Excellence engagement (commercial life-sciences win); (2) a new NACCHO (National Association of County and City Health Officials) award, deepening existing relationship; and (3) additional commercial and public-health work. Work scope includes business continuity, disaster recovery, cybersecurity assessments, program management, organizational change management, and AI capabilities. This represents execution of the company's stated strategy to expand commercial healthcare and life-sciences revenue beyond its government and public-safety base.
Why this rating
For a $10.1M market-cap company, ~$800K annualized recurring revenue is ~8% of market value—meaningful but not transformational. Significance driven by strategic validation (stated market strategy executed), account penetration (pharma/healthcare entry), and recurring revenue character. Material as proof of commercial pivot; not game-changing unless contracts extend materially or lead to major upsells.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.